Training program in the biology and translational research on Alzheimer's disease and related dementias

摘要 此T32应用程序寻求支持对阿尔茨海默病实习生的多学科教育，并 相关痴呆症(ADRD)。神经科学，包括分子和细胞机制的基础生物学 老龄化、表观遗传学和性别，是ADRD培训计划(ADRD-TP)的核心。然而，该计划 将包括药物发现和开发、临床和转化研究(包括创业)、 以及生物信息学、生物物理学和数据科学。导师/导师团队拥有卓越的专业知识 建立这一创新的跨学科培训计划，以整合原本截然不同的 在UIC和Rush的卓越表现，受到行业合作的影响。它将提供新兴的、 对神经退行性变和痴呆症的多学科理解，学员需要重振 搜索治疗方法和治疗方法。我们将满足对科学家的迫切需求，他们能够合成出 纪律。从痴呆症的分子机制、血管生物学到糖尿病，专家的专长是多种多样的 以及炎症、神经和神经影像对人类ADRD患者的临床诊断和大规模应用 数据分析。专业知识来自11个系(解剖学和细胞生物学、神经学、精神病学、医学、 药理学、麻醉学、生物工程、计算机科学、药物化学、化学和 运动学)5个学院(医学、药学、工程、文科、应用健康科学)，5个临床 和翻译实体(拉什的阿尔茨海默病研究中心、老龄化和记忆诊所 UIC、UIC组织储存库和UIC健康与老龄化研究中心、 UIC的临床翻译科学(CCTS)。我们将培训不同背景的ADRD研究人员 跨学科技能，包括神经科学家，但也包括计算生物学家和感兴趣的工程师 在翻译ADRD研究中。为了促进跨学科培训，受训者将有一名主要导师。 和二级导师；后者利用来自多个学科的同事的技能。我们将建立个人 每个受训人员的发展计划(IDP)，并提供ADRD-TP教师的多学科课程，但 还有制药科学家。重要的是，学员可以在4个附属临床和研究中心中的1个进行翻译研究 翻译实体。将鼓励学员与NIH支持的大型社区合作 研究(ROS/MAP或NIA的大型合作联盟、AMP-AD、M20VE-AD、ADNI、ACTC)以及 我们的行业合作伙伴，礼来公司和艾伯维。鼓励学员参加CCTS的工作坊， 面向组学和药物发现的芝加哥生物医学联盟(CBC) CIM/Matter创业计划，帮助科学创新商业化。我们寻求支持 4名研究生。在学员的导师和利用境内流离失所者的情况下，将在整个过程中监测进展情况 培训，由个别论文委员会进行。总之，ADRD-TP将提供一个严格的、鼓舞人心的和 培育环境，确保培训揭开痴呆症所需的最高水平的科学家。

ABSTRACT This T32 application seeks support for the multidisciplinary education of trainees in Alzheimer's disease and related dementia (ADRD). Neuroscience, including Basic Biology of molecular and cellular mechanisms of aging, epigenetics and gender, is the core of the ADRD training program (ADRD-TP). However, the program will include Drug Discovery and Development, Clinical and Translational Research including entrepreneurship, and Bioinformatics, Biophysics and Data Science. The mentor/preceptor team has outstanding expertise to establish this innovative, interdisciplinary training program, to integrate otherwise disparate centers of excellence at UIC and Rush, leveraged by industry collaborations. It will provide training in the emerging, multidisciplinary understanding of neurodegeneration and dementia, that trainees need to reinvigorate the search for treatments and cures. We will answer the imperative need for scientists who can synthesize across disciplines. Preceptor expertise is diverse; from molecular mechanisms of dementia, vascular biology, diabetes and inflammation, neuronal and neural imaging to clinical diagnosis of human ADRD patients and large scale data analysis. Expertise is from 11 departments (Anatomy and Cell Biology, Neurology, Psychiatry, Medicine, Pharmacology, Anesthesiology, Bioengineering, Computer science, Medicinal Chemistry, Chemistry, and Kinesiology) 5 colleges (Medicine, Pharmacy, Engineering, Liberal Arts, Applied health sciences), 5 clinical and translational entities (The Alzheimer's Disease Research Center at Rush, the Aging and Memory Clinic at UIC, the UIC tissue repository bank and the Center for Research on Health and Aging at UIC, the Center for Clinical Translation Science (CCTS) at UIC). We will train ADRD researchers with diverse backgrounds and cross-disciplinary skills, including neuroscientists, but also computational biologists, and engineers interested in translational ADRD research. To facilitate interdisciplinary training, trainees will have a primary preceptor and secondary mentor; the latter utilizing skills of associates from many disciplines. We will build individual development plans (IDPs) for each trainee and offer multidisciplinary coursework from ADRD-TP faculty but also pharma scientists. Importantly, trainees can perform translational research at 1 of 4 affiliated clinical and translational entities. Trainees will be encouraged to collaborate with large community-based NIH-supported studies (ROS/MAP or NIA's large-scale collaborative consortia, AMP-AD, M2OVE-AD, ADNI, ACTC), and with our industry partners, Eli Lilly and AbbVie. Trainees are encouraged to participate in workshops of the CCTS, the Chicago Biomedical Consortium (CBC) that is geared towards -omics and drug discovery and the CIM/MATTER entrepreneurial program that aids commercialization of scientific innovation. We seek to support 4 graduate students. With the trainee's mentors and utilizing IDPs, progress will be monitored throughout training, by individual thesis committees. In summary, the ADRD-TP will provide a rigorous, inspiring and nurturing environment to ensure training of the highest level of scientists needed to unravel dementia.